Develops hematopoietic stem cell therapies for the treatment of hematologic malignancies.
Vor Biopharma, Inc. is a pioneering clinical-stage company specializing in the development of engineered hematopoietic stem cell (eHSC) therapies designed for cancer patients. At the forefront of its research is VOR33, an innovative eHSC product candidate currently undergoing phase 1/2 clinical trials. VOR33 aims to address acute myeloid leukemia (AML) and other hematological malignancies by leveraging eHSCs that lack CD33, a protein typically expressed by AML blood cancer cells.
In addition to its lead candidate, Vor Biopharma is advancing a pipeline of targeted eHSC therapies, including CAR-Ts (chimeric antigen receptor T cells), bispecific antibodies, and antibody-drug conjugates. These therapies are tailored to provide precision treatment solutions for various blood cancers, highlighting the company's commitment to advancing personalized medicine approaches.
Established in 2015 and headquartered in Cambridge, Massachusetts, Vor Biopharma operates at the forefront of biotechnological innovation. The company has strategically partnered with Akron BioProducts to collaborate on the development and manufacturing of cGMP nucleases, reinforcing its capabilities in gene editing technologies crucial for advancing its therapeutic pipeline.
Driven by a mission to transform cancer treatment paradigms, Vor Biopharma continues to expand its scientific expertise and collaborative efforts. Through pioneering research and strategic partnerships, the company aims to deliver breakthrough therapies that offer new hope to patients facing challenging hematological conditions worldwide.